JP2017533265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533265A5 JP2017533265A5 JP2017542212A JP2017542212A JP2017533265A5 JP 2017533265 A5 JP2017533265 A5 JP 2017533265A5 JP 2017542212 A JP2017542212 A JP 2017542212A JP 2017542212 A JP2017542212 A JP 2017542212A JP 2017533265 A5 JP2017533265 A5 JP 2017533265A5
- Authority
- JP
- Japan
- Prior art keywords
- range
- concentration
- minoxidil
- alopecia
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004384 Alopecia Diseases 0.000 claims 22
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims 20
- 229960003632 minoxidil Drugs 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 18
- 229960002256 spironolactone Drugs 0.000 claims 11
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 11
- 208000024963 hair loss Diseases 0.000 claims 10
- 230000003676 hair loss Effects 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 9
- 231100000360 alopecia Toxicity 0.000 claims 8
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 6
- 229960000997 bicalutamide Drugs 0.000 claims 6
- 229960000978 cyproterone acetate Drugs 0.000 claims 5
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 5
- 229960004199 dutasteride Drugs 0.000 claims 5
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims 5
- 229960004671 enzalutamide Drugs 0.000 claims 5
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 5
- 229960004039 finasteride Drugs 0.000 claims 5
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 5
- 229960002074 flutamide Drugs 0.000 claims 5
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 5
- 229960002653 nilutamide Drugs 0.000 claims 5
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- 230000000284 resting effect Effects 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 241000202807 Glycyrrhiza Species 0.000 claims 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 229940083712 aldosterone antagonist Drugs 0.000 claims 2
- 239000002170 aldosterone antagonist Substances 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000002996 androgenic alopecia Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000002280 anti-androgenic effect Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- 210000004209 hair Anatomy 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940010454 licorice Drugs 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 239000003956 nonsteroidal anti androgen Substances 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 208000003024 Diffuse alopecia Diseases 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014904327A AU2014904327A0 (en) | 2014-10-29 | Detection and treatment of excessive hair shedding | |
| AU2014904327 | 2014-10-29 | ||
| PCT/AU2015/050682 WO2016065426A1 (en) | 2014-10-29 | 2015-10-29 | Detection and treatment of excessive hair shedding |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067194A Division JP2020109127A (ja) | 2014-10-29 | 2020-04-03 | 過剰な毛髪脱落の検出及び処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533265A JP2017533265A (ja) | 2017-11-09 |
| JP2017533265A5 true JP2017533265A5 (enExample) | 2018-09-27 |
| JP6915946B2 JP6915946B2 (ja) | 2021-08-11 |
Family
ID=55856287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542212A Active JP6915946B2 (ja) | 2014-10-29 | 2015-10-29 | 過剰な毛髪脱落の検出及び処置 |
| JP2020067194A Pending JP2020109127A (ja) | 2014-10-29 | 2020-04-03 | 過剰な毛髪脱落の検出及び処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067194A Pending JP2020109127A (ja) | 2014-10-29 | 2020-04-03 | 過剰な毛髪脱落の検出及び処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10226462B2 (enExample) |
| EP (2) | EP3626244B1 (enExample) |
| JP (2) | JP6915946B2 (enExample) |
| KR (2) | KR20240011239A (enExample) |
| CN (2) | CN107106560A (enExample) |
| AU (4) | AU2015337807B2 (enExample) |
| CA (2) | CA3209849A1 (enExample) |
| ES (2) | ES2773467T3 (enExample) |
| NZ (1) | NZ732075A (enExample) |
| SG (2) | SG10202002705YA (enExample) |
| WO (1) | WO2016065426A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106560A (zh) | 2014-10-29 | 2017-08-29 | 萨姆森临床私人有限公司 | 毛发过度脱落的检测和治疗 |
| WO2018093465A1 (en) | 2016-11-21 | 2018-05-24 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| US20180189976A1 (en) | 2016-12-29 | 2018-07-05 | Michal Kasprzak | Analysis unit and system for assessment of hair condition |
| SG11202000124PA (en) * | 2017-07-12 | 2020-02-27 | Samson Clinical Pty Ltd | Promoting hair growth and treatment of hair loss or excessive hair shedding |
| US20220079911A1 (en) * | 2018-09-13 | 2022-03-17 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| CN109674762A (zh) * | 2019-03-05 | 2019-04-26 | 南京正大天晴制药有限公司 | 一种度他雄胺及治疗脱发的组合物胶囊 |
| CN110478450B (zh) * | 2019-10-09 | 2021-04-13 | 北海鑫臻药业有限公司 | 一种治疗阿尔茨海默病的药物组合物及其应用 |
| CN111110721A (zh) * | 2020-01-19 | 2020-05-08 | 朱炜 | 一种毛发防脱再生的复合制剂及其使用方法 |
| CN115136191B (zh) * | 2020-02-27 | 2025-03-25 | 松下知识产权经营株式会社 | 图像处理装置及图像处理方法 |
| CA3233426A1 (en) * | 2021-09-29 | 2023-04-06 | Animesh SINHA | Hair loss therapy |
| US11744788B2 (en) * | 2021-10-27 | 2023-09-05 | James D. Welch | Method of encouraging growth and regrowth of hair in human males technical area |
| JP2025536556A (ja) | 2022-10-25 | 2025-11-07 | ヴェラダーミクス インコーポレイテッド | 放出調節ミノキシジル用組成物および使用方法 |
| WO2025048828A1 (en) * | 2023-09-01 | 2025-03-06 | Follea International | Compositions and methods for an oral supplement to oral minoxidil for the treatment of alopecia |
| US20250213594A1 (en) * | 2023-12-27 | 2025-07-03 | Inventage Lab Inc. | Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997643A (en) | 1989-07-12 | 1991-03-05 | Union Carbide Chemicals And Plastics Company Inc. | Polymeric salt delivery systems |
| WO1992008705A1 (en) * | 1990-11-14 | 1992-05-29 | The Upjohn Company | 5-fluoro-2,4,6-pyrimidinetriamine compounds |
| US5407944A (en) | 1993-02-19 | 1995-04-18 | Goldman; Boris E. | Compositions and methods for promoting hair growth |
| GB2314019B (en) * | 1996-06-10 | 2000-03-15 | Bio Scient Ltd | The use of L-Lysine in the treatment of hair loss |
| AU2406299A (en) | 1998-02-12 | 1999-08-30 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
| JP2000038340A (ja) | 1998-05-20 | 2000-02-08 | Kumahiro Miyama | 育毛剤および食品 |
| JP2003012542A (ja) | 2001-06-26 | 2003-01-15 | Toray Ind Inc | 発毛促進剤 |
| US20050271596A1 (en) | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| JPWO2006038315A1 (ja) | 2004-10-07 | 2008-07-31 | 株式会社サンギ | 経皮・経粘膜吸収製剤 |
| US20080064765A1 (en) | 2006-09-11 | 2008-03-13 | Jacob Birnbaum | Novel hair growth compositions and methods for treating hair loss or related claims |
| WO2008067158A2 (en) * | 2006-11-13 | 2008-06-05 | Auxagen, Inc. | METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR |
| DK2344198T3 (da) * | 2008-09-27 | 2020-11-30 | Jina Pharmaceuticals Inc | Lipidbaserede farmaceutiske præparater til topisk anvendelse |
| US8691518B2 (en) * | 2010-09-24 | 2014-04-08 | Global Life Science Partners Limited | Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia |
| EP2510930A1 (en) | 2011-04-15 | 2012-10-17 | Bionanoplus, S.L. | Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof |
| AU2011100917B4 (en) * | 2011-07-26 | 2013-05-02 | Sinclair, Rodney Daniel Professor | Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens |
| WO2013181487A2 (en) | 2012-05-31 | 2013-12-05 | Stiefel Laboratories, Inc. | Method of treating |
| CN107106560A (zh) | 2014-10-29 | 2017-08-29 | 萨姆森临床私人有限公司 | 毛发过度脱落的检测和治疗 |
| US9561224B1 (en) | 2015-05-27 | 2017-02-07 | Moshe Rogosnitzky | Methods and compositions for treating androgenetic alopecia |
| SG11202000124PA (en) | 2017-07-12 | 2020-02-27 | Samson Clinical Pty Ltd | Promoting hair growth and treatment of hair loss or excessive hair shedding |
-
2015
- 2015-10-29 CN CN201580061561.5A patent/CN107106560A/zh active Pending
- 2015-10-29 CA CA3209849A patent/CA3209849A1/en active Pending
- 2015-10-29 ES ES15854489T patent/ES2773467T3/es active Active
- 2015-10-29 SG SG10202002705YA patent/SG10202002705YA/en unknown
- 2015-10-29 KR KR1020247000993A patent/KR20240011239A/ko not_active Ceased
- 2015-10-29 CN CN202310057359.1A patent/CN115998740A/zh active Pending
- 2015-10-29 JP JP2017542212A patent/JP6915946B2/ja active Active
- 2015-10-29 WO PCT/AU2015/050682 patent/WO2016065426A1/en not_active Ceased
- 2015-10-29 SG SG11201703424WA patent/SG11201703424WA/en unknown
- 2015-10-29 US US15/522,599 patent/US10226462B2/en active Active
- 2015-10-29 EP EP19205898.0A patent/EP3626244B1/en active Active
- 2015-10-29 CA CA3003940A patent/CA3003940C/en active Active
- 2015-10-29 EP EP15854489.0A patent/EP3212192B1/en active Active
- 2015-10-29 KR KR1020177014272A patent/KR102625061B1/ko active Active
- 2015-10-29 NZ NZ732075A patent/NZ732075A/en unknown
- 2015-10-29 AU AU2015337807A patent/AU2015337807B2/en active Active
- 2015-10-29 ES ES19205898T patent/ES2952159T3/es active Active
-
2017
- 2017-08-01 AU AU2017210523A patent/AU2017210523B2/en active Active
-
2018
- 2018-12-17 AU AU2018279055A patent/AU2018279055A1/en not_active Abandoned
-
2019
- 2019-01-18 US US16/252,107 patent/US11116770B2/en active Active
-
2020
- 2020-04-03 JP JP2020067194A patent/JP2020109127A/ja active Pending
- 2020-06-04 AU AU2020203695A patent/AU2020203695B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533265A5 (enExample) | ||
| US20200121680A1 (en) | Methods of administering elagolix | |
| SG11201907038WA (en) | Quinazoline compound | |
| FI3452039T3 (fi) | Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä | |
| MX2024007853A (es) | Composicion farmaceutica que comprende un compuesto de quinazolina. | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| MY209708A (en) | Niraparib formulations | |
| NZ590796A (en) | Film-forming liquid formulations for drug release to hair and scalp | |
| JP2016540738A5 (enExample) | ||
| NZ744567A (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| JP2019516684A5 (enExample) | ||
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| JO2792B1 (en) | Dietary supplement and method for the treatment of digestive disorders | |
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| EA201291089A1 (ru) | Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций | |
| JP2020527146A5 (enExample) | ||
| MX2023001445A (es) | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. | |
| AU2011100917B4 (en) | Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens | |
| MX2021004198A (es) | Suplemento dietetico humano y metodo para tratar trastornos del sistema digestivo y los relacionados con el sistema inmunologico. | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| WO2018158225A1 (en) | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof | |
| JP2019509309A5 (enExample) | ||
| YU100303A (sh) | Pedijatrijski oblik gatifloksacina |